Cas9 nickase–mediated contraction of CAG/CTG repeats is associated with phenotypic improvements in a Huntington’s disease mouse model
Authors:
- Alvaro MurilloAMAlvaro Murillo
- Melanie AlpaughMAMelanie Alpaugh
- Ruban Rex Peter DurairajRDRuban Rex Peter Durairaj
- Emma L. RandallEREmma L. Randall
- Meghan LarinMLMeghan Larin
- Laura HeratyLHLaura Heraty
- Alys N. AstonAAAlys N. Aston
- Alysha S. TaylorATAlysha S. Taylor
- Alex Mas MonteysAMAlex Mas Monteys
- Nina StöberlNSNina Stöberl
- Aeverie E. R. HeuchanAHAeverie E. R. Heuchan
- Pascale AeschlimannPAPascale Aeschlimann
- 21 October 2026
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (872) , eaef9466
Abstract
Expanded CAG/CTG repeats cause more than 15 different diseases that all remain without a disease-modifying treatment. Because repeat length accounts for most of the variation in disease severity, contracting CAG/CTG repeats presents an attractive therapeutic avenue. Here, we show that the CRISPR-Cas9 nickase targeted to CAG/CTG repeats leads to efficient repeat contractions in Huntington’s disease (HD) patient–derived neurons and astrocytes and in myotonic dystrophy type 1 patient–derived neurons. The approach was allele selective and free of detectable off-target mutations. Injection of the Cas9 nickase into the striatum of the R6/1 mouse model of HD using adeno-associated viral vectors led to repeat contractions in more than half of striatal neurons. Upon injection, we observed a reduction in the number of inclusion bodies, an improved gene expression profile, and amelioration of locomotion deficits in the open field test. The effects were greater than expected from the contractions induced, suggesting that non–cell autonomous mechanisms may be involved. Our results provide the proof of concept that correction of CAG/CTG repeats can improve HD phenotypes in a mouse disease model.Keywords
Funding Information
- Myotonic Dystrophy Foundation (N/A)
- CHDI Foundation (N/A)
- Huntington Society of Canada (N/A)
- Medical Research Council (MR/X02184X/1)
- Medical Research Council (MR/T033428/1)
- Academy of Medical Sciences (AMSPR1\1014)
- European Research Council (813851)
- UK Dementia Research Institute (DRI-TAP2022FA2)
- UK Dementia Research Institute (DRI-TAP2022FA14)
- UK Dementia Research Institute (UK DRI-3204)
- The Sigrid Rausing Trust (UCL Neurogenetic Therapies Programme)
- Moondance Foundation Laboratories (N/A)
- Neuroscience and Mental Health Innovation Institute (N/A)
This publication has 78 references indexed in Scilit:
- Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1Clinical and Translational Medicine, 2025
- Therapeutic targeting of mismatch repair proteins in triplet repeat expansion diseasesDNA Repair, 2025
- Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s diseaseCell, 2025
- The myotonic dystrophy type 1 drug development pipeline: 2022 editionDrug Discovery Today, 2023
- Neuronal and astrocytic contributions to Huntington’s disease dissected with zinc finger protein transcriptional repressorsCell Reports, 2023
- Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editingJournal of Molecular Medicine, 2020
- CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease OnsetCell, 2019
- The Self-Inactivating KamiCas9 System for the Editing of CNS Disease GenesCell Reports, 2017
- Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic miceBrain Research Bulletin, 2012
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993